Navigation Links
Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial

f ribavirin, and pegylated interferon alpha 2a; and patients in arm C (n=39) received placebo, weight- based dosing of ribavirin and pegylated interferon alpha 2a. For all patients in this study there was a seven day lead-in period, where patients received either valopicitabine or placebo alone; the additional components of each arm's therapeutic regimen were administered beginning on day eight.

The primary endpoint of the study was to assess pharmacokinetic and pharmacodynamic drug-drug interaction between valopicitabine and ribavirin after 36 days of treatment. Drug levels for both NM107 (the active form of valopicitabine) and ribavirin when administered alone or together were within the range of 80 to 125 percent, indicating the lack of an interaction. At day 36, 23 percent of patients treated with triple combination therapy (arm B) were HCV PCR-negative per protocol, compared to 11 percent of patients treated with the standard of care (arm C) and 14 percent of patients treated with valopicitabine and pegylated interferon (arm A). These findings demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin.

The key secondary endpoints for the study were antiviral activity, safety and tolerability at 12 weeks. Of patients that completed 12 weeks of therapy, 72.2 percent of patients treated with triple combination therapy (arm B) achieved HCV PCR-negativity, compared to 61.5 percent of patients treated with the standard of care (arm C). There were three discontinuations from the study, all due to adverse events (AEs), one of which was attributed by the clinical investigator to valopicitabine-related gastrointestinal toxicity. The two other AEs, including a serious adverse event (SAE), were attributed by the clinical investigators to pegylated interferon or pegylated interferon/ribavirin. All of the discontinuations occurred in the triple combination arm (arm B).

At the end of 12 weeks, patients we
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
3. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
4. Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
5. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
8. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
9. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
10. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
11. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Post Your Comments:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: MRK ... and Canada , is teaming with celebrity ... Diabetes: Logra Tus Metas , an educational program encouraging Hispanics with ... -- a key treatment goal to help reduce the risk of ... are at a higher risk for developing type 2 diabetes ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
(Date:9/20/2014)... Sept. 19, 2014 (HealthDay News) -- The avian flu ... 2011 could be spread through respiratory drops and therefore ... new study. Although no human illnesses have been ... Jude Children,s Research hospital have discovered natural mutations to ... to travel through the air in droplets. Current ...
(Date:9/20/2014)... New York (PRWEB) September 20, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries ... yet another insurer has announced plans to end ... posted on its website last month, Harrisburg, Pennsylvania-based ... effective November 1, 2014. The insurer said its ...
(Date:9/20/2014)... PA (PRWEB) September 20, 2014 "As a ... in their tanks," said an inventor from Tamaqua, Pa. "The ... mounted on the backs of their chairs. My invention enables ... developed the Kam Oxygen Sensor to make it easier to ... that the user knows when the tank is low. It ...
(Date:9/20/2014)... 20, 2014 RBSEO Services, which has ... companies, has announced it provides an affordable website SEO ... , This announcement would benefit those new and old ... but cannot afford to pay a big amount for ... of their websites in top search results for their ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
Breaking Medicine News(10 mins):Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2
... A new comparison of the procedures to help prevent ... of the neck concludes they are equally effective at ... surgery or a minimally invasive treatment using wire coils ... six percent. Results of the analysis were detailed in ...
... blood test to help diagnose major depressive disorder indicates ... a paper published in the journal Molecular Psychiatry ... reports that a test analyzing levels of nine biomarkers ... without significant false-positive results. "Traditionally, ...
... Reinberg HealthDay Reporter , TUESDAY, Jan. 31 ... to control indigestion and heartburn may put themselves at ... use of these drugs, called proton pump inhibitors (PPIs), ... percent for current or former smokers, the researchers added. ...
... you are a people-pleaser who strives to keep your social ... certain social situations like Super Bowl watch parties. A new ... not, some people eat in an attempt to keep others ... upset the sense of social harmony," says Julie Exline, a ...
... TUESDAY, Jan. 31 (HealthDay News) -- Physicians can boost their chances ... flexible sigmoidoscopy test, which is a less invasive procedure than ... at the value of following up a negative flexible sigmoidoscopy test ... repeat test. However, "you don,t find twice as many [signs ...
... new therapies and data on the relative benefits of ... advance of the fourth annual Genitourinary Cancers Symposium, being ... Marquis in San Francisco, Calif. The results of ... briefing via live webcast): 1) Vigorous Exercise Linked ...
Cached Medicine News:Health News:Stents and surgery for blocked neck arteries are neck-and-neck as lasting stroke prevention 2Health News:Stents and surgery for blocked neck arteries are neck-and-neck as lasting stroke prevention 3Health News:Blood test accurately distinguishes depressed patients from healthy controls 2Health News:Blood test accurately distinguishes depressed patients from healthy controls 3Health News:Heartburn Drugs May Raise Fracture Risk in Older Women 2Health News:Heartburn Drugs May Raise Fracture Risk in Older Women 3Health News:Hold the extra burgers and fries when people pleasers arrive 2Health News:Alternative to Colonoscopy Spots Cancers, Too 2Health News:Research from the 2012 Genitourinary Cancers Symposium highlights new treatments, compares existing therapies for prostate cancer 2
... of doublet objective and high power negative ... 3.0x. The true benefit of this system ... focal clarity is made possible due to ... lightweight aluminum bar and individual interpupillary adjustment ...
Used for maintaining and forming the anterior chamber by the injection and removal of fluids, air miotics, and viscoeastic substances, as well as keeping the cornea moist during surgery. 4 mm from be...
23 gauge cannula (E4969 L) with 0.33 mm aspiration port, curved shaft and polished finish. Includes Teflon irrigating sleeve (E4969 SL). Uses 60 cm (23.6 inches) of silicone tubing (N5941 5). Overall...
... with five legs for extra stability. ... 25" (total vertical travel 6"). 2" ... Comfortable, durable and fire retardant upholstery, ... other colors available by special order. ...
Medicine Products: